only they can profit big off the new drug.. Dr. John Campbell 1.29M subscribers New Pfizer antiviral and ivermectin, a pharmacodynamic analysis New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄ PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-rel... So, what is a protease? So what is a protease inhibitor? And, what is 3CL? Chymotrypsin-like protease (3CL main protease, or 3CL Mpro) Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020) https://pubs.acs.org/doi/abs/10.1021/... The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection https://pubs.rsc.org/en/content/artic... the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket: Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents https://www.nature.com/articles/s4200... as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration. Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly. Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study https://pubs.rsc.org/en/content/artic... From the docking analysis, ivermectin showed the highest docking score with an average energy of −8